Madrigal Pharmaceuticals
Akero fails to meet NASH trial endpoint, hurting other players in the field
Anika Sharma
The landscape of Nonalcoholic Steatohepatitis (NASH) appeared promising with Madrigal Therapeutics taking steps toward treatment approval. However, this optimism was ...
Madrigal’s NASH drug gets fast-track review from FDA, no panel needed
Anika Sharma
In the wake of a recent CEO transition, Madrigal Pharmaceuticals has disclosed that its nonalcoholic steatohepatitis (NASH) drug has been ...
